These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16361013)

  • 21. Orphan drugs and orphan tests in the USA.
    Thoene JG
    Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
    [No Abstract]   [Full Text] [Related]  

  • 22. [Orphan diseases, rare diseases, time to get mobilised].
    Cordier JF
    Rev Prat; 2006 Jan; 56(2):123-4. PubMed ID: 16584035
    [No Abstract]   [Full Text] [Related]  

  • 23. A decade of optimizing drug development for rare neuromuscular disorders through TACT.
    Wagner KR; De Luca A; Caizergues D; Dowling J; Goemans N; Gordish-Dressman H; Grounds MD; Kelly M; Mayhew A; McNally EM; Zoetis T; Lee J; Turner C; Wells DJ; Csimma C; Straub V
    Nat Rev Drug Discov; 2020 Jan; 19(1):1-2. PubMed ID: 31907422
    [No Abstract]   [Full Text] [Related]  

  • 24. Orphan drug designation and development in Japan: 25 years of experience and assessment.
    Sakushima K; Takeda H; Aoi Y
    Nat Rev Drug Discov; 2021 Dec; 20(12):893-894. PubMed ID: 33723413
    [No Abstract]   [Full Text] [Related]  

  • 25. Translation of rare disease research into orphan drug development: disease matters.
    Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
    Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Orphan products: hope for people with rare diseases.
    Rados C
    FDA Consum; 2003; 37(6):10-5. PubMed ID: 14986582
    [No Abstract]   [Full Text] [Related]  

  • 27. Is it time to revisit orphan drug policies?
    McCabe C; Stafinski T; Menon D
    BMJ; 2010 Sep; 341():c4777. PubMed ID: 20861098
    [No Abstract]   [Full Text] [Related]  

  • 28. A human-on-a-chip approach to tackling rare diseases.
    de Mello CPP; Rumsey J; Slaughter V; Hickman JJ
    Drug Discov Today; 2019 Nov; 24(11):2139-2151. PubMed ID: 31412288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Orphan drugs--medications for patients with rare diseases].
    Thielke D; Thyssen JP; Hansen BJ
    Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.
    Herder M
    Account Res; 2013; 20(4):227-69. PubMed ID: 23805831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ethical considerations in orphan drug approval and use.
    Kesselheim AS
    Clin Pharmacol Ther; 2012 Aug; 92(2):153-5. PubMed ID: 22814660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Animal models for metabolic, neuromuscular and ophthalmological rare diseases.
    Vaquer G; Rivière F; Mavris M; Bignami F; Llinares-Garcia J; Westermark K; Sepodes B
    Nat Rev Drug Discov; 2013 Apr; 12(4):287-305. PubMed ID: 23493083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

  • 34. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.
    Wood J; Sames L; Moore A; Ekins S
    Drug Discov Today; 2013 Nov; 18(21-22):1043-51. PubMed ID: 23968993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of orphan drug policies in treating rare diseases.
    Weerasooriya SU
    Health Info Libr J; 2019 Jun; 36(2):179-184. PubMed ID: 30933412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I; Breckenridge A
    Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rare diseases, orphan drugs, and orphaned patients.
    Scheindlin S
    Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
    [No Abstract]   [Full Text] [Related]  

  • 39. Orphan drugs and the NHS: consider whom drug regulation is designed to protect.
    Marshall T
    BMJ; 2005 Nov; 331(7525):1144. PubMed ID: 16282417
    [No Abstract]   [Full Text] [Related]  

  • 40. Orphan drugs revisited.
    McCabe C; Tsuchiya A; Claxton K; Raftery J
    QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.